miRNAs and ovarian cancer: An overview

Journal of Cellular Physiology

Volumn 233, Issue 5, 2018, Pages 3846-3854

  Deb, Bornali ^a   Uddin, Arif ^b   Chakraborty, Supriyo ^a  

^a ASSAM UNIVERSITY   (India)

^b Moinul Hoque Choudhury memorial Science College   (India)

Author keywords

gynecologic malignancy; miRNA; ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MICRORNA; PROTEIN P53;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; CIRCULATION; EPIGENETICS; GENE EXPRESSION PROFILING; HUMAN; NORTHERN BLOTTING; OVARY CANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA ISOLATION; WESTERN BLOTTING; ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; METABOLISM; OVARY TUMOR; PROCEDURES; PROGNOSIS;

ANIMALS; CARCINOMA, OVARIAN EPITHELIAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 85028353163     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.26095     Document Type: Review

References (92)

1. Barik, S. (2008). An intronic microRNA silences genes that are functionally antagonistic to its host gene. Nucleic Acids Research, 36, 5232–5241.
2. Bartels, C. L., & Tsongalis, G. J. (2009). MicroRNAs: Novel biomarkers for human cancer. Clinical Chemistry, 55, 623–631.
3. Baskerville, S., & Bartel, D. P. (2005). Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. Ribonucleic Acid, 11, 241–247.
4. Bell, D. A. (2005). Origins and molecular pathology of ovarian cancer. Modern Pathology, 18, S19–S32.
5. Boeri, M., Verri, C., Conte, D., Roz, L., Modena, P., Facchinetti, F., … Sozzi, G. (2011). MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proceedings of the National Academy of Sciences, 108, 3713–3718.
6. Bohnsack, M. T., Czaplinski, K., & GÖRLICH, D. (2004). Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. Ribonucleic Acid, 10, 185–191.
7. Calin, G. A., & Croce, C. M. (2006). MicroRNA-cancer connection: The beginning of a new tale. Cancer Research, 66, 7390–7394.
8. Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., & Negrini, M. … (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America, 101, 2999–3004.
9. Calin, G. A., Ferracin, M., Cimmino, A., Di Leva, G., Shimizu, M., Wojcik, S. E., & Fabbri, M. … (2005). A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. New England Journal of Medicine, 353, 1793–1801.
10. Calura, E., Fruscio, R., Paracchini, L., Bignotti, E., Ravaggi, A., Martini, P., … Ceppi, L. (2013). MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. Clinical Cancer Research, 19, 4114–4123.
11. Chen, R., Alvero, A., Silasi, D., Kelly, M., Fest, S., Visintin, I., … Mor, G. (2008). Regulation of IKKβ by miR-199a affects NF-κB activity in ovarian cancer cells. Oncogene, 27, 4712–4723.
12. Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., … Guo, X. (2008). Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research, 18, 997–1006.
13. Cittelly, D. M., Dimitrova, I., Howe, E. N., Cochrane, D. R., Jean, A., Spoelstra, N. S., … Spillman, M. A. (2012). Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Molecular Cancer Therapeutics, 11, 2556–2565.
14. Chung, Y.-W., Bae, H.-S., Song, J.-Y., Lee, J. K., Lee, N. W., Kim, T., & Lee, K.-w (2013). Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patient. International Journal of Gynecological Cancer, 23, 673–679.
15. Cochrane, D. R., Spoelstra, N. S., Howe, E. N., Nordeen, S. K., & Richer, J. K. (2009). MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Molecular Cancer Therapeutics, 8, 1055–1066.
16. Corney, D. C., Flesken-Nikitin, A., Choi, J., & Nikitin, A. Y. (2008). Role of p53 and Rb in Ovarian Cancer. Ithaca, NY: Ovarian Cancer, Springer (pp. 99–117).
17. Corney, D. C., Hwang, C.-I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A. K., … Hermeking, H. (2010). Frequent downregulation of miR-34 family in human ovarian cancers. Clinical Cancer Research, 16, 1119–1128.
18. Creighton, C. J., Nagaraja, A. K., Hanash, S. M., Matzuk, M. M., & Gunaratne, P. H. (2008). A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. Ribonucleic Acid, 14, 2290–2296.
19. Creighton, C. J., Fountain, M. D., Yu, Z., Nagaraja, A. K., Zhu, H., Khan, M., … Matzuk, M. M. (2010). Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Research, 70, 1906–1915.
20. Croce, C. M. (2009). Causes and consequences of microRNA dysregulation in cancer. Nature Reviews Genetics, 10, 704–714.
21. Cullen, B. R. (2004). Transcription and processing of human microRNA precursors. Molecular Cell, 16, 861–865.
22. Dahiya, N., & Morin, P. J. (2010). MicroRNAs in ovarian carcinomas. Endocrine-Related Cancer, 17, F77–F89.
23. Di Leva, G., & Croce, C. M. (2010). Roles of small RNAs in tumor formation. Trends in Molecular Medicine, 16, 257–267.
24. Di Leva, G., & Croce, C. M. (2013). The role of microRNAs in the tumorigenesis of ovarian cancer. Frontiers in Oncology, 3, 153.
25. Dwivedi, S. K. D., Mustafi, S. B., Mangala, L. S., Jiang, D., Pradeep, S., Rodriguez-Aguayo, C., … Calin, G. A. (2016). Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget, 7, 15093.
26. Esquela-Kerscher, A., & Slack, F. J. (2006). Oncomirs—microRNAs with a role in cancer. Nature Reviews Cancer, 6, 259–269.
27. Feeley, K., & Wells, M. (2001). Precursor lesions of ovarian epithelial malignancy. Histopathology, 38, 87–95.
28. Feng, G., Li, G., Gentil-Perret, A., Tostain, J., & Genin, C. (2008). Elevated serum-circulating RNA in patients with conventional renal cell cancer. Anticancer Research, 28, 321–326.
29. Flavin, R., Smyth, P., Barrett, C., Russell, S., Wen, H., Wei, J., … Denning, K. (2009). MiR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. International Journal of Gynecological Cancer, 19, 641–647.
30. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001). Cancer statistics, 2001. CA: A Cancer Journal for Clinicians, 51, 15–36.
31. Han, H. S., Yun, J., Sn, L., Han, J. H., Lee, K. H., Kim, S. T., … Choi, S. Y. (2013). Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. International Journal of Cancer, 133, 645–652.
32. He, W. A., Calore, F., Londhe, P., Canella, A., Guttridge, D. C., & Croce, C. M. (2014). Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proceedings of the National Academy of Sciences, 111, 4525–4529.
33. Hu, X., Macdonald, D. M., Huettner, P. C., Feng, Z., El Naqa, I. M., Schwarz, J. K., & Wang, X. … (2009). A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecologic Oncology, 114, 457–464.
34. Huang, Y., Shen, X. J., Zou, Q., Wang, S. P., Tang, S. M., & Zhang, G. Z. (2011). Biological functions of microRNAs: A review. Journal of Physiology and Biochemistry, 67, 129–139.
35. Iorio, M. V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Casalini, P., & Alder, H. … (2007). MicroRNA signatures in human ovarian cancer. Cancer Research, 67, 8699–8707.
36. Janssen, H. L., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., … Zhou, Y. (2013). Treatment of HCV infection by targeting microRNA. New England Journal of Medicine, 368, 1685–1694.
37. John, B., Sander, C., & Marks, D. S. (2006). Prediction of human microRNA targets. MicroRNA Protocols, 342, 101–113.
38. John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., & Marks, D. S. (2004). Human microRNA targets. PLoS Biology, 2, e363.
39. Karginov, F. V., Conaco, C., Xuan, Z., Schmidt, B. H., Parker, J. S., Mandel, G., & Hannon, G. J. (2007). A biochemical approach to identifying microRNA targets. Proceedings of the National Academy of Sciences, 104, 19291–19296.
40. Kinose, Y., Sawada, K., Nakamura, K., & Kimura, T. (2014). The role of microRNAs in ovarian cancer. BioMed Research International, 2014, https://doi.org/10.1155/2014/249393
41. Kosaka, N., Iguchi, H., Yoshioka, Y., Takeshita, F., Matsuki, Y., & Ochiya, T. (2010). Secretory mechanisms and intercellular transfer of microRNAs in living cells. Journal of Biological Chemistry, 285, 17442–17452.
42. Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., & Stoffel, M. … (2005). Combinatorial microRNA target predictions. Nature Genetics, 37, 495–500.
43. Krol, J., Loedige, I., & Filipowicz, W. (2010). The widespread regulation of microRNA biogenesis, function and decay. Nature Reviews Genetics, 11, 597–610.
44. Kumar, M. S., Lu, J., Mercer, K. L., Golub, T. R., & Jacks, T. (2007). Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genetics, 39, 673–677.
45. Laios, A., O'Toole, S., Flavin, R., Martin, C., Kelly, L., Ring, M., … Gleeson, N. (2008). Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Molecular Cancer, 7, 35.
46. Lawrie, C. H., Gal, S., Dunlop, H. M., Pushkaran, B., Liggins, A. P., Pulford, K., … Wainscoat, J. S. (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. British Journal of Haematology, 141, 672–675.
47. Lee, C.-H., Subramanian, S., Beck, A. H., Espinosa, I., Senz, J., Zhu, S. X., … Gilks, C. B. (2009). MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS ONE, 4, e7314.
48. Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75, 843–854.
49. Lewis, B. P., Shih, I.-, Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003). Prediction of mammalian microRNA targets. Cell, 115, 787–798.
50. Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., … Johnson, J. M. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature, 433, 769–773.
51. Maragkakis, M., Reczko, M., Simossis, V. A., Alexiou, P., Papadopoulos, G. L., Dalamagas, T., … Kourtis, K. (2009). DIANA-microT web server: Elucidating microRNA functions through target prediction. Nucleic Acids Research, gkp292.
52. Marcus, C. S., Maxwell, G. L., Darcy, K. M., Hamilton, C. A., & McGuire, W. P. (2014). Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. Journal of Cancer, 5, 25–30.
53. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., … Davidson, M. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine, 334, 1–6.
54. Miles, G. D., Seiler, M., Rodriguez, L., Rajagopal, G., & Bhanot, G. (2012). Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Research Notes, 5, 164.
55. Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., … Allen, A. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences, 105, 10513–10518.
56. Nagaraja, A. K., Creighton, C. J., Yu, Z., Zhu, H., Gunaratne, P. H., Reid, J. G., … Hawkins, S. M. (2010). A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Molecular Endocrinology, 24, 447–463.
57. Nakamura, K., Sawada, K., Yoshimura, A., Kinose, Y., Nakatsuka, E., & Kimura, T. (2016). Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Molecular Cancer, 15, 48.
58. Nam, E. J., Yoon, H., Kim, S. W., Kim, H., Kim, Y. T., Kim, J. H., … Kim, S. (2008). MicroRNA expression profiles in serous ovarian carcinoma. Clinical Cancer Research, 14, 2690–2695.
59. Network CGAR. (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609–615.
60. Nikitin, A. Y., & Corney, D. C. (2008). MicroRNA and ovarian cancer. Histology and Histopathology, 1161–1169.
61. Ohyagi-Hara, C., Sawada, K., Kamiura, S., Tomita, Y., Isobe, A., Hashimoto, K., … Takahashi, T. (2013). miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin α5 expression. The American Journal of Pathology, 182, 1876–1889.
62. Parikh, A., Lee, C., Joseph, P., Marchini, S., Baccarini, A., Kolev, V., … Wang, F. (2014). MicroRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nature Communications, 5. https://doi.org/10.1038/ncomms3977
63. Park, N. J., Zhou, H., Elashoff, D., Henson, B. S., Kastratovic, D. A., Abemayor, E., & Wong, D. T. (2009). Salivary microRNA: Discovery, characterization, and clinical utility for oral cancer detection. Clinical Cancer Research, 15, 5473–5477.
64. Pecot, C. V., Rupaimoole, R., Yang, D., Akbani, R., Ivan, C., Lu, C., … Rodriguez-Aguayo, C. (2013). Tumour angiogenesis regulation by the miR-200 family. Nature Communications, 4, 2427.
65. Perera, R. J., & Ray, A. (2007). MicroRNAs in the search for understanding human diseases. BioDrugs, 21, 97–104.
66. Pratt, A. J., & MacRae, I. J. (2009). The RNA-induced silencing complex: A versatile gene-silencing machine. Journal of Biological Chemistry, 284, 17897–17901.
67. Preston, C. C., Maurer, M. J., Oberg, A. L., Visscher, D. W., Kalli, K. R., Hartmann, L. C., … Knutson, K. L. (2013). The ratios of CD8+ T cells to CD4+ CD25+ FOXP3+ and FOXP3-T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS ONE, 8, e80063.
68. Rehmsmeier, M., Steffen, P., Höchsmann, M., & Giegerich, R. (2004). Fast and effective prediction of microRNA/target duplexes. Ribonucleic Acid, 10, 1507–1517.
69. Rossi, S., Sevignani, C., Nnadi, S. C., Siracusa, L. D., & Calin, G. A. (2008). Cancer-associated genomic regions (CAGRs) and noncoding RNAs: Bioinformatics and therapeutic implications. Mammalian Genome, 19, 526.
70. Sawada, K., Mitra, A. K., Radjabi, A. R., Bhaskar, V., Kistner, E. O., Tretiakova, M., … Kenny, H. A. (2008). Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target. Cancer Research, 68, 2329–2339.
71. Saito, Y., Liang, G., Egger, G., Friedman, J. M., Chuang, J. C., Coetzee, G. A., & Jones, P. A. (2006). Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell, 9, 435–443.
72. Sethupathy, P., Corda, B., & Hatzigeorgiou, A. G. (2006). TarBase: A comprehensive database of experimentally supported animal microRNA targets. Ribonucleic Acid, 12, 192–197.
73. Shell, S., Park, S.-M., Radjabi, A. R., Schickel, R., Kistner, E. O., Jewell, D. A., & Peter, M. E. (2007). Let-7 expression defines two differentiation stages of cancer. Proceedings of the National Academy of Sciences, 104, 11400–11405.
74. Shen, J., Ambrosone, C. B., DiCioccio, R. A., Odunsi, K., Lele, S. B., & Zhao, H. (2008). A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis, 29, 1963–1966.
75. Taylor, D. D., & Gercel-Taylor, C. (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecologic Oncology, 110, 13–21.
76. Tibshirani, R., Hastie, T., Narasimhan, B., & Chu, G. (2002). Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proceedings of the National Academy of Sciences, 99, 6567–6572.
77. Tusher, V. G., Tibshirani, R., & Chu, G. (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences, 98, 5116–5121.
78. Vaksman, O., Stavnes, H. T., Kærn, J., Trope, C. G., Davidson, B., & Reich, R. (2011). MiRNA profiling along tumour progression in ovarian carcinoma. Journal of Cellular and Molecular Medicine, 15, 1593–1602.
79. Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology, 9, 654–659.
80. Vang, S., Wu, H.-T., Fischer, A., Miller, D. H., MacLaughlan, S., Douglass, E., … Brard, L. (2013). Identification of ovarian cancer metastatic miRNAs. PLoS ONE, 8, e58226.
81. Vatolin, S., Navaratne, K., & Weil, R. J. (2006). A novel method to detect functional microRNA targets. Journal of Molecular Biology, 358, 983–996.
82. Vinther, J., Hedegaard, M. M., Gardner, P. P., Andersen, J. S., & Arctander, P. (2006). Identification of miRNA targets with stable isotope labeling by amino acids in cell culture. Nucleic Acids Research, 34, e107–e107.
83. Vogt, M., Munding, J., Grüner, M., Liffers, S.-T., Verdoodt, B., Hauk, J., … Hermeking, H. (2011). Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Archiv, 458, 313–322.
84. Wang, S., Xiang, J., Li, Z., Lu, S., Hu, J., Gao, X., … Wu, Y. (2015). A plasma microRNA panel for early detection of colorectal cancer. International Journal of Cancer, 136, 152–161.
85. Wheeler, B. M., Heimberg, A. M., Moy, V. N., Sperling, E. A., Holstein, T. W., Heber, S., & Peterson, K. J. (2009). The deep evolution of metazoan microRNAs. Evolution & Development, 11, 50–68.
86. Wright, G. W., & Simon, R. M. (2003). A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics, 19, 2448–2455.
87. Yang, H., Kong, W., He, L., Zhao, J.-J., O'Donnell, J. D., Wang, J., … Nicosia, S. V. (2008). MicroRNA expression profiling in human ovarian cancer: MiR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Research, 68, 425–433.
88. Zeng, Y., & Cullen, B. R. (2004). Structural requirements for pre-microRNA binding and nuclear export by Exportin 5. Nucleic Acids Research, 32, 4776–4785.
89. Zhang, L., Huang, J., Yang, N., Greshock, J., Megraw, M. S., Giannakakis, A., … Ward, M. R. (2006). MicroRNAs exhibit high frequency genomic alterations in human cancer. Proceedings of the National Academy of Sciences, 103, 9136–9141.
90. Zhang, L., Volinia, S., Bonome, T., Calin, G. A., Greshock, J., Yang, N., … Hasegawa, K. (2008). Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proceedings of the National Academy of Sciences, 105, 7004–7009.
91. Zhang, S., Lu, Z., Unruh, A. K., Ivan, C., Baggerly, K. A., … Le, X.-F. (2015). Clinically relevant microRNAs in ovarian cancer. Molecular Cancer Research, 13, 393–401.
92. Zheng, H., Zhang, L., Zhao, Y., Yang, D., Song, F., Wen, Y., … Chen, K. (2013). Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS ONE, 8, e77853.